Birmingham, ALNCT04362644Now EnrollingIRB Ready

Idiopathic Pulmonary Fibrosis Clinical Trial in Birmingham, AL

Access cutting-edge idiopathic pulmonary fibrosis treatment through this clinical trial at a research site in Birmingham. Study-provided care at no cost to qualified participants.

Sponsored by University of Alabama at Birmingham

Quick Self-Assessment

See if you qualify for this Birmingham location

Preparing your pre-screening questions…

Expert Care in Birmingham

Access idiopathic pulmonary fibrosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related idiopathic pulmonary fibrosis treatment provided free

Apply for This Birmingham Location

Check if you qualify for this idiopathic pulmonary fibrosis clinical trial in Birmingham, AL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Birmingham

    Convenient for AL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Birmingham site if eligible
  4. 4Begin participation

About This Idiopathic Pulmonary Fibrosis Study in Birmingham

The purpose of the study is to see if imaging with fluorine-18 Fluorodeoxyglucose (\[18F\] FDG) and fluorine-18 Displacement Per Atom (\[18F\]DPA-714) using positron emission tomography and computed tomography (PET/CT) will show lung inflammation and fibrosis in patients diagnosed with idiopathic pulmonary fibrosis (IPF). This study may help physicians and researchers better understand how best to treat patients with IPF in the future.

Sponsor: University of Alabama at Birmingham

Who Can Participate

Inclusion Criteria

Age between 40-85 years old.
A diagnosis of IPF that fulfills American Thoracic Society (ATS) / European Respiratory Society (ERS) 2018 consensus criteria within 5 years.
Ability and willingness to give informed consent and adhere to study requirements.
Ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) \>0.70.
High or mixed affinity binder for TSPO ligands based on genotyping for single-nucleotide polymorphism (SNP)rs6971.

Exclusion Criteria

Acute exacerbation of IPF within \<30 days
Diagnosis of Diabetes Mellitus (Type 1 or Type 2).
Diagnoses of current infection by clinical or microbial assessments.
Treatment for \>14 days within the preceding month with \>20 mg. prednisone (or equivalent) or any treatment during the last month with a cellular immunosuppressant.
Subjects with prior radiation therapy to the thorax.
Women who are pregnant, or who are breastfeeding. IPF is a disease of older adults, and male predominant, so this will not be a frequent consideration.
Severe cardiovascular disease, defined as any of the following within the preceding 12 weeks: acute myocardial infarction or unstable angina, a coronary revascularization procedure, or stroke.
Subjects with known liver disease.
Diagnosis of any active cancer with the exception of basal cell carcinoma of skin.
Low affinity binder for TSPO ligands based on genotyping for SNP rs6971.
Active cigarette smoking or vaping

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Birmingham?

Yes, this clinical trial (NCT04362644) has an active research site in Birmingham, AL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Idiopathic Pulmonary Fibrosis Treatment Options in Birmingham, AL

If you're searching for idiopathic pulmonary fibrosis treatment options in Birmingham, AL, this clinical trial (NCT04362644) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Birmingham research site is actively enrolling participants for this clinical trial. You'll receive care from experienced idiopathic pulmonary fibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all idiopathic pulmonary fibrosis clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Fibrosis Trials in Birmingham, AL

See all pulmonary fibrosis clinical trials recruiting in Birmingham — not just this study.

Browse Pulmonary Fibrosis Trials in Birmingham →

Browse More Trials by Condition

Pulmonary Fibrosis TrialsInterstitial Cystitis TrialsFibromyalgia TrialsInterstitial Lung Disease TrialsAll Conditions →

Ready to Join in Birmingham?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Birmingham, AL